Treating age-related eye disease through improved ocular perfusion.
OcuDyne is a clinical stage medical device company focused on treating various ocular health conditions by improving blood flow to the eye.
The first indication that OcuDyne is pursuing is Age Related Macular Degeneration (AMD).
Age Related Macular Degeneration (AMD) is a chronic eye disorder that causes blurred vision or a central blind spot. AMD worsens over time.
OcuDyne’s novel therapy capitalizes on a new and revolutionary hypothesis about the underlying cause of AMD.
Age Related Macular Degeneration (AMD) is a chronic eye disorder that causes blurred vision or a central blind spot. AMD worsens over time; starting as dry AMD with gradual vision loss and sometimes advancing to wet AMD with rapid vision loss. Dry AMD is caused by drusen (lipid) particles that collect under the retina, and wet AMD is caused by abnormal blood vessels that leak fluid or blood into the macula. Wet AMD may be treated with regular anti VEGF injections into the eye that essentially convert wet AMD back to dry AMD.
OcuDyne is developing a series of minimally invasive therapeutic devices designed to improve blood flow to the eye.
OcuDyne is currently conducting clinical trials in Argentina and Australia.